Cambridge Enterprise

Cambridge Enterprise is the commercialization arm of the University of Cambridge, established to assist students and staff in bringing their ideas and expertise to market. Founded in 2006, it serves as a resource for members of the University and the Babraham Institute, providing competitive early-stage seed funding through initiatives like the Challenge Fund and the Venture Fund. Its focus is primarily on investments in the life sciences and medical technology sectors, promoting co-investment and follow-on funding to facilitate the commercialization of inventions developed within the university. With a rich history dating back to 1209, the University of Cambridge is a leading global academic institution that conducts extensive research across various fields and actively engages in the development and commercialization of intellectual property.

Dr Loukik Arora

Senior Investment Associate

Past deals in Generation Z

Zetta Genomics

Seed Round in 2022
Zetta Genomics is a Cambridge-based company established in 2018 that focuses on managing large-scale genomic data to advance precision medicine. The company operates a user-centric platform that facilitates connections between individuals and researchers, allowing users to opt in or out of studies related to various health conditions, including common disorders like eczema and diabetes, as well as rare diseases such as muscular dystrophy. By employing distributed database technology and robust security measures, Zetta Genomics ensures the privacy of genomic data while enabling scientists to access dynamic health and genetic datasets for personalized medicine research. The platform emphasizes transparency and control for users throughout the data-sharing process.

Z Factor

Series A in 2017
Z Factor Limited is a drug discovery company based in Cambridge, United Kingdom, established in 2014. The company focuses on identifying and developing therapeutic agents to address alpha-1-antitrypsin deficiency, a genetic disorder that leads to significant health complications. Z Factor's research aims to design novel therapeutic solutions that correct the misfolding of the Z variant of alpha-1-antitrypsin, addressing a critical medical need. Current treatment options are limited, primarily relying on lung or liver transplantation and augmentation therapy. Through its innovative approach, Z Factor seeks to create effective therapies that could improve the quality of life for those affected by this condition.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.